Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a
CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced
solid tumors (Phase 1) and subjects with relapsed/recurrent GBM (Phase 2). The study is
designed to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of
USL311 alone and in combination with lomustine.